Vulto AG - Search Results

1

Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.

Visser LE, Penning-van Bees FJ, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, Stricker BH. Visser LE, et al. Among authors: vulto ag. Thromb Haemost. 2002 Nov;88(5):705-10. Thromb Haemost. 2002. PMID: 12428081

2

Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants.

Visser LE, Penning-van Beest FJ, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, Stricker BH. Visser LE, et al. Among authors: vulto ag. Clin Pharmacol Ther. 2002 Jun;71(6):496-502. doi: 10.1067/mcp.2002.124470. Clin Pharmacol Ther. 2002. PMID: 12087353

3

Acute renal failure after local gentamicin treatment in an infected total knee arthroplasty.

van Raaij TM, Visser LE, Vulto AG, Verhaar JA. van Raaij TM, et al. Among authors: vulto ag. J Arthroplasty. 2002 Oct;17(7):948-50. doi: 10.1054/arth.2002.34525. J Arthroplasty. 2002. PMID: 12375257

4

Overanticoagulation associated with combined use of lactulose and acenocoumarol or phenprocoumon.

Visser LE, Penning-van Beest FJ, Wilson JH, Vulto AG, Kasbergen AA, De Smet PA, Hofman A, Stricker BH. Visser LE, et al. Among authors: vulto ag. Br J Clin Pharmacol. 2004 Apr;57(4):522-4. doi: 10.1046/j.1365-2125.2003.02036.x. Br J Clin Pharmacol. 2004. PMID: 15025752 Free PMC article.

5

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.

Visser LE, van Vliet M, van Schaik RH, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH. Visser LE, et al. Among authors: vulto ag. Pharmacogenetics. 2004 Jan;14(1):27-33. doi: 10.1097/00008571-200401000-00003. Pharmacogenetics. 2004. PMID: 15128048

6

The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.

Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH. Visser LE, et al. Among authors: vulto ag. Thromb Haemost. 2004 Jul;92(1):61-6. doi: 10.1160/TH03-12-0741. Thromb Haemost. 2004. PMID: 15213846

7

The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants.

Visser LE, Bleumink GS, Trienekens PH, Vulto AG, Hofman A, Stricker BH. Visser LE, et al. Among authors: vulto ag. Br J Haematol. 2004 Oct;127(1):85-9. doi: 10.1111/j.1365-2141.2004.05162.x. Br J Haematol. 2004. PMID: 15384981 Free article.

8

Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants.

Visser LE, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH. Visser LE, et al. Among authors: vulto ag. Pharmacogenet Genomics. 2005 Feb;15(2):69-74. doi: 10.1097/01213011-200502000-00002. Pharmacogenet Genomics. 2005. PMID: 15861030

9

Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.

Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH. Visser LE, et al. Among authors: vulto ag. Clin Pharmacol Ther. 2005 Jun;77(6):479-85. doi: 10.1016/j.clpt.2005.02.009. Clin Pharmacol Ther. 2005. PMID: 15961979

10

Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.

Bijl MJ, Visser LE, Hofman A, Vulto AG, van Gelder T, Stricker BH, van Schaik RH. Bijl MJ, et al. Among authors: vulto ag. Br J Clin Pharmacol. 2008 Apr;65(4):558-64. doi: 10.1111/j.1365-2125.2007.03052.x. Epub 2007 Dec 7. Br J Clin Pharmacol. 2008. PMID: 18070221 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

205 results

Search Page

Filters